Latest filings (excl ownership)
6-K
Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024
25 Apr 24
6-K
Virax Biolabs Group Limited to Participate at ESCMID Global 2024
16 Apr 24
6-K
Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency
15 Mar 24
6-K
Current report (foreign)
22 Jan 24
424B5
Prospectus supplement for primary offering
22 Jan 24
6-K
Current report (foreign)
12 Jan 24
6-K
Current report (foreign)
21 Dec 23
424B3
Prospectus supplement
20 Dec 23
6-K
Current report (foreign)
20 Dec 23
424B3
Prospectus supplement
20 Dec 23
6-K
Virax Biolabs’ CEO James Foster Issues Letter to Shareholders
18 Dec 23
EFFECT
Notice of effectiveness
18 Dec 23
6-K
Virax Biolabs Group Limited Announces 1-for-10 Share Consolidation
14 Dec 23
CORRESP
Correspondence with SEC
13 Dec 23
UPLOAD
Letter from SEC
12 Dec 23
6-K
Current report (foreign)
8 Dec 23
F-3
Shelf registration (foreign)
5 Dec 23
6-K
Current report (foreign)
8 Nov 23
6-K
Current report (foreign)
31 Oct 23
D
$2.15 mm in equity / options / securities to be acquired, sold $2.15 mm, 1 investor
17 Oct 23
6-K
Current report (foreign)
12 Oct 23
6-K
Current report (foreign)
4 Oct 23
6-K
Virax Biolabs Group Announces Early-Access Program Launch of Research Use Only ViraxImmune Product and Hosts Webinar
12 Sep 23
6-K
Virax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth Momentum
1 Sep 23
6-K
Nasdaq Approves 180-Day Extension for Virax Biolabs Group to Meet Minimum $1 Bid
3 Aug 23
6-K
Virax Biolabs Group Continues Growth and Expansion with the Addition of Research and Laboratory Facilities
18 Jul 23
20-F
2023 FY
Annual report (foreign)
14 Jun 23
6-K
Virax Biolabs' CEO James Foster Issues Letter to Shareholders
14 Jun 23
6-K
Virax Biolabs Group Announces Establishment of Regional Headquarters at Dubai Science Park
4 May 23
6-K
Current report (foreign)
21 Apr 23
6-K
Virax Biolabs Group Limited Has Entered into an Agreement for the Distribution of Marburg Virus PCR Testing Kits
19 Apr 23
424B3
Prospectus supplement
31 Mar 23
EFFECT
Notice of effectiveness
30 Mar 23
CORRESP
Correspondence with SEC
28 Mar 23
UPLOAD
Letter from SEC
28 Mar 23
F-1
Registration statement (foreign)
22 Mar 23
D
$4.00 mm in equity / options / securities to be acquired, sold $4.00 mm, 1 investor
15 Mar 23
6-K
Virax Biolabs Group Limited Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
10 Mar 23
6-K
Current report (foreign)
7 Mar 23
6-K
Current report (foreign)
7 Feb 23
Latest ownership filings